Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
Does your lung cancer's genetic makeup change how well immune therapy works?
This narrative review explores how targetable driver gene alterations in non-small cell lung cancer (NSCLC) influence the tumor immune micro…
Lung cancer's genetic drivers actively reshape the tumor's immune environment, causing immunotherapy to work differently depending on a pati…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease.
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition. It argues that i…
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
Combined neutrophil-to-lymphocyte ratio predicts progression-free survival in metastatic cervical cancer patients treated with immune checkpoint inhibitors.
A Simple Blood Test May Predict Cervical Cancer Treatment Success
This retrospective cohort analysis evaluated 148 individuals with metastatic or recurrent cervical cancer treated with immune checkpoint inh…
A simple blood test ratio may predict who responds best to immunotherapy for advanced cervical cancer, helping doctors tailor treatment with…
Immune Checkpoint Inhibitors Improve Survival and Response Rates in Patients with Hepatocellular Carcinoma Compared to Standard Therapy
New Drug Gives Liver Cancer Patients More Time
This systematic review and meta-analysis evaluated immune checkpoint inhibitors (ICIs) versus standard therapy or placebo in patients with h…
A new drug helps the immune system fight liver cancer, giving patients more time and better survival rates compared to standard treatments.
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma
The Liver Cancer Treatment That Works Better Depending on Your History
This systematic review and meta-analysis of seventeen studies evaluated immune checkpoint inhibitor (ICI)-based regimens versus tyrosine kin…
Immunotherapy beats older drugs for advanced liver cancer, especially when hepatitis B caused the disease, but benefits depend on your liver…
In L858R-mutated NSCLC, ICI combinations improve progression-free survival versus chemotherapy in TKI-resistant patients.
Immune Drugs Work in This Lung Cancer, But Only as a Team
This systematic review and meta-analysis evaluated immune checkpoint inhibitor (ICI)-based treatments in EGFR L858R-mutated non-small cell l…
For lung cancer patients with a specific mutation, immune drugs alone fail but work when combined with other treatments to delay progression…
In lung cancer patients, immune-checkpoint inhibitors were associated with a 16.4% incidence of thyroid irAEs.
Thyroid Trouble Might Mean Better Lung Cancer Response
This retrospective analysis of 420 lung cancer patients treated with immune-checkpoint inhibitors at a single Italian center found that 16.4…
Having a mild thyroid reaction while on cancer drugs could actually mean the medicine is working well inside your body.
Meta-analysis finds immunotherapy efficacy in HCC varies by aetiology, strongest in HBV-related disease
1. HEADLINE
A systematic review and meta-analysis of 26 studies in hepatocellular carcinoma found immune checkpoint inhibitor efficacy varies by aetiolo…
For the first time, a major analysis confirms that *why* you have liver cancer is a powerful clue to *if* a leading treatment will help you …
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier.
Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.…
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Risk models for ICI-associated myocarditis occurrence and severity in patients receiving immune checkpoint inhibitors
Can blood tests and heart signals predict dangerous heart inflammation from cancer drugs?
This retrospective unmatched case-control study evaluated baseline biomarkers and combined signatures in 196 patients receiving immune check…
A mix of blood tests and heart rhythm checks can predict dangerous heart inflammation from cancer drugs with better accuracy than blood work…